Why Generic Software Will Fail at Price Optimisation in Life Sciences

And what a vertical, tender-aware, evidence-linked approach (like Vamstar’s) does differently.

Generic price-optimisation platforms—built for retail, travel, or horizontal B2B—struggle in Pharma, MedTech, and Biotech because the optimisation problem is fundamentally different. Life-sciences pricing is constrained by tender mechanics, external/ international reference pricing (ERP/IRP), health technology assessment (HTA) and value-based procurement (VBP), and policy shocks. These conditions demand models that read policy and tender text, simulate sealed-bid outcomes, respect cross-border price linkages, and integrate clinical-economic value. Horizontal tools are not designed for this.

Life-sciences pricing is not a retail problem

Tender-driven demand. In many markets, a single national or regional tender sets price and volume for years; the “demand curve” is discontinuous and winner-takes-most. Standard elasticity models learned from high-frequency, transactional data don’t apply. IQVIA’s landscape review shows tendering dominates procurement for originals, biosimilars, generics, and vaccines across Europe.

ERP/IRP linkages. Dozens of countries peg price ceilings to baskets of other countries; a move in one market can cascade through others. OECD and peer-reviewed reviews document the pervasiveness of IRP/ERP and the spillovers this creates. Any optimiser that maximises local revenue without ERP constraints risks triggering cross-market price compression.

HTA and cost-effectiveness. In the UK and other systems, HTA (e.g., NICE) evaluates clinical and cost effectiveness; funding and price are tied to value and ICERs, not just willingness to pay. Optimisation must ingest HTA guidance and thresholds.

VBP and MEAT scoring. In devices especially, contracts are awarded on most economically advantageous tender (MEAT)—a weighted score across price, outcomes, quality, total cost of care, sustainability—not lowest price. Price is one factor in a multi-attribute auction.

Centralised buyers. Saudi Arabia’s NUPCO and GCC joint procurement concentrate demand and enforce framework agreements—massively altering pricing power and the bid calculus.

Tendering is an auction, not “dynamic pricing”

Hospital and payer tenders are often first-price sealed-bid or multi-winner procurement auctions with quality/technical scoring. Optimal bidding here requires bid-shading under uncertainty, competitor count modelling, and winner’s-curse mitigation—concepts from auction theory that generic retail/ticketing optimisers simply don’t implement.

Empirical work on procurement shows:

• • Additional competitors reduce prices materially (≈5% per extra bidder in analogue drug tenders).
  • “Winner’s curse” dynamics are real in procurement (under-estimating costs → unsustainable bids → supply risk).

If your optimiser cannot simulate sealed-bid tender outcomes with quality weights, it will over- or under-shade bids and destroy margin or lose share.

The data-generating process is sparse, policy-constrained, and text-heavy

Sparse events. Many SKUs face a handful of lumpy tenders per year—not millions of daily transactions. Models must learn from low-frequency, high-stakes events and transfer learn across countries and lines, not from clickstreams.

Text is the spec. Eligibility clauses, service levels, penalties, and equivalence rules live in PDFs and portals, not neat columns. Optimisers must parse and reason over tender/contract text—not just numbers. (Generic tools rarely read source tender documents.)

Policy shocks. Procurement rules change quickly: e.g., the EU recently barred most Chinese medical-device bids over €5m under the International Procurement Instrument—instantly altering feasible supplier sets and price baselines. Optimisers must incorporate such shocks into scenario planning.

Supply fragility. Aggressive price pressure can induce shortages; recent reporting shows shortages in essential generics when economics turn non-viable. Optimisers need guardrails for sustainable pricing, not just lowest bid.